Open public hearings
This article was originally published in The Tan Sheet
Executive Summary
Individuals who wish to present during open public hearings at advisory committee meetings are not required to disclose financial ties, FDA says in a draft guidance published in the Federal Register Feb. 15. Although disclosure is encouraged, panelists should not ask further questions about a potential link, but may ask for further details on scientific content, the draft guidance adds...
You may also be interested in...
Open Public Hearing Speakers Should Disclose Financial Conflict – Comments
FDA should permit advisory committee members and voting consultants to question open public hearing speakers about their potential conflicts of interest during advisory committee meetings, according to the consumer advocacy group Public Citizen
Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug
Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.
Biogen’s RoActemra Biosimilar Begins EU Approvals Process
The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.